In the Journals

Strength training ‘recovers lost muscle mass’ from cirrhosis

August 20, 2019
Supervised progressive resistance training increased muscle strength and size in patients with compensated cirrhosis while also providing beneficial…

Terlipressin reverses hepatorenal syndrome in phase 3 trial

August 19, 2019
Initial results from a phase 3 clinical study of terlipressin showed that the therapy met its primary endpoint of “verified” hepatorenal…

In the Journals

Models calculate risk for post-hepatectomy liver failure in cirrhosis

August 17, 2019
A pair of preoperative and postoperative models estimated the probabilities for post-hepatectomy liver failure in patients with cirrhosis, according…

Pediatric hepatology: 6 reports on treating liver disease in children

August 15, 2019
Liver disease in children and adolescents takes on as many forms as in adults, including viral hepatitis, autoimmune diseases, fatty liver disease…

Enrollment begins for phase 2a trial of hepatic encephalopathy therapy

August 14, 2019
Mallinckrodt announced the first patient has been enrolled in a phase 2a trial comparing MNK-6106, an L-ornithine phenylacetate, with Xifaxan for the…

In the Journals

Multistrain probiotic improves cognitive complications in cirrhosis

July 30, 2019
Intake of a multistrain probiotic improved cognitive function, risk for falls and inflammatory response in patients with cirrhosis and a history of…

In the Journals

Global prevalence of concurrent NAFLD in type 2 diabetes at 55%

July 30, 2019
Results from a systematic review and meta-analysis revealed the global prevalence of fatty liver disease in patients with type 2 diabetes, ranging…

ShearWave Elastography predicts mortality in chronic liver disease

July 25, 2019
Liver stiffness measured by 2D ShearWave Elastography demonstrated significant predictive value in the progression of chronic liver disease including…

In the Journals

ACG releases clinical guideline for hereditary hemochromatosis

July 24, 2019
The American College of Gastroenterology released a new clinical guideline for the screening, diagnosis and treatment of hereditary hemochromatosis…

NAFLD, NASH leading 'economic tsunami' of liver disease in US

July 22, 2019
Stephen A. Harrison, MD, FACP, FAASLD, visiting professor of hepatology at University of Oxford and medical director at Pinnacle Clinical Research…


AASLD Foundation presents grants to young hepatologists for research, careers

July 18, 2019
The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and career development awards to 29…

Dicerna readies alpha-1 antitrypsin deficiency-related liver disease drug for trial

July 2, 2019
Dicerna Pharmaceuticals submitted a clinical trial authorization application to the Swedish Medical Products Agency to conduct a phase 1/2 study of…

FDA grants fast track to alpha-1 antitrypsin deficiency-related liver disease drug

June 28, 2019
The FDA granted fast track designation to ARO-AAT, Arrowhead Pharmaceuticals’ second generation subcutaneously administered RNA interference…

Cirrhosis update: 5 reports on improving patient care

June 21, 2019
Cirrhosis, or late stage fibrosis, can result from a variety of causes including progression from nonalcoholic fatty liver disease and very often…

In the Journals

Patients with severe psoriasis at risk for advanced liver fibrosis

June 11, 2019
Patients with central obesity, insulin resistance and active psoriasis are at high risk for liver fibrosis, according to researchers from…


High-dose albumin reduces systemic inflammation in cirrhosis

June 4, 2019
Treatment with high-dose levels of albumin reduced systemic inflammation and cardiocirculatory dysfunction in patients with decompensated cirrhosis…

Mallinckrodt completes phase 3 enrollment for hepatorenal syndrome drug

May 15, 2019
Mallinckrodt achieved target enrollment of 300 participants for a phase 3 clinical study designed to evaluate the safety and efficacy of terlipressin…

Alcohol-related hepatitis therapy lowers Lille score, bilirubin, MELD

May 13, 2019
Durect Corporation announced preliminary data from an ongoing phase 2a trial of DUR-928 for alcohol-related hepatitis, according to a press release…

In the Journals

Advanced practice providers make difference in cirrhosis care quality

May 8, 2019
Patients with cirrhosis had improved quality of care and outcomes when treated by advanced practice providers compared with those without such care…

In the Journals

Fibrosis stages worsening in alcoholic fatty liver disease cases

May 7, 2019
Although the prevalence of alcoholic fatty liver disease among U.S. adults remained stable between 2001 and 2016, the prevalence of those with stage…